EAST SETAUKET, NY, March 03, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the virtual 33rd Annual Roth Conference, being held March 15-17, 2021. Investors may register and consult the conference agenda at the event website.

Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *